Stifel reiterates Buy on Kestra Medical stock, cites strong growth

Kestra Medical reported fiscal Q1 2027 revenue of $31.0 million, up 60% year over year and about $2 million above the $29.0 million consensus estimate, while gross margin rose 175bps sequentially to 56.5%. The company lifted full-year revenue guidance to $141 million from $137 million, signaling continued demand and share gains in wearable cardioverter defibrillators. However, its $0.75 per-share loss was materially wider than the $0.45 analyst forecast, contributing to a notable after-hours share decline despite Stifel maintaining a Buy rating and $30 price target.

Analysis

KMTS now has a classic high-growth medtech valuation problem: the operating indicators support a higher revenue base, but the earnings miss implies that incremental commercial investment and/or operating leakage remains ahead of scale benefits. The key question for the next 1-3 months is whether the guidance increase is primarily a pull-forward of rental starts or reflects durable improvement in prescriptions converting into reimbursable revenue. A sustained fill-rate and payer-mix improvement would make the current revenue trajectory materially more valuable than a one-quarter shipment or territory-expansion spike.

The competitive read-through is unfavorable for ZOLL/Asahi Kasei, the incumbent wearable cardioverter-defibrillator platform, because KMTS appears to be winning where workflow, patient adherence, and reimbursement execution matter as much as device performance. However, incumbents can respond through contracting, pricing, and sales-force intensity; a reduction in KMTS's gross-margin progression would be the first evidence that share gains are becoming costly. The rental model also embeds working-capital and collections risk: revenue growth can outpace cash conversion if reimbursement timing deteriorates.

The after-hours weakness is directionally rational, but the market may be over-focusing on a single-quarter loss rather than the slope of gross margin and revenue guidance. For a sub-$2B, still-lossmaking company, multiple expansion requires credible visibility to operating leverage; absent explicit FY27 cash-burn, sales-and-marketing, and EBITDA targets, this is not yet a clean fundamental long. The decisive catalyst is the next quarterly update: repeat revenue outperformance plus stable-to-higher gross margin would force estimates higher, while any cut to growth guidance or margin below the mid-50s would expose the stock to a sharp de-rating.

Key Decisions for Investors

• Keep KMTS on a post-earnings watchlist rather than initiate immediately. Consider a 1-3 month long only if shares stabilize and management or subsequent disclosures confirm reimbursement collections and fill-rate gains are persisting; target a retest of the $30 analyst target versus a stop on a guidance reduction or gross margin falling below 55%.
• For existing KMTS exposure, reduce position size until cash-burn and operating-expense cadence are clarified. The risk is not demand but a delayed path to profitability, which can compress the revenue multiple even if sales continue to beat.
• Monitor ZOLL parent Asahi Kasei (3407 JP) and, where accessible, broader cardiac-rhythm peers such as MDT and ABT for evidence of price or contracting response. A visible defensive response would weaken the thesis that KMTS can convert share gains into durable margin expansion.
• Set an alert for the next earnings release: upgrade to a tactical long if revenue growth remains above 40%, gross margin expands sequentially, and loss per share narrows with no acceleration in cash use; avoid or short rallies if revenue guidance holds but losses widen again, signaling growth is being purchased through commercial spend.